H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $42 from $38 and keeps a Buy rating on the shares following the Q3 report. The company’s lung sales were inline with expectations while a Japan approval could provide a turnaround in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVCR:
- Novocure reports Q3 EPS (33c), consensus (42c)
- NVCR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment
- NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment
- NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment